FIGURE 5.

Effective chemo‐immunotherapy in tumor‐recurrence GL261 model mice. (A) Schematic timeline of the GL261‐Luc GBM anti‐recurrence efficacy study. Tumors were initially surgically resected on day 7 and mice were then intravenously injected with ABNM@TMZ/OTX, ABNM@TMZ, ABNM@OTX, free TMZ/OTX, free TMZ (5.0 mg TMZ equiv./kg and/or 5.0 mg OTX equiv./kg) or PBS on days 10 and 13 post tumor implantation. (B) Bioluminescent signal images of mice bearing orthotopic GL261‐Luc GBM recurrence tumor after treatment as described in (A). (C) Quantified luminescence levels of orthotopic GL261‐Luc tumor in mice following treatment as described in (A). (D) Mice survival rates. (E) Representative flow cytometry dot plots and (F) statistical data of the expression of memory immune cells in the spleen from GL261‐Luc (gated on CD62L and CD44 T cells). Quantification of the infiltration of CD4⁺ and CD8⁺ T cells in (G,H) blood and (I,J) tumor by flow cytometry in recurrent GL261‐Luc model mice on day 19 after treatment as described in (A). Expression of CD4⁺ and CD8⁺ markers by staining with anti‐CD4‐FITC and anti‐CD8‐APC in tumor and blood. Mice treated with PBS were used as controls